Conformationally restricted butyrophenones with mixed dopaminergic (D2) and serotoninergic (5-HT(2A)) affinities. Synthesis of 5-aminoethyl-and 6- aminomethyl-4-oxotetrahydroindoles as potential atypical antipsychotics

Chemical and Pharmaceutical Bulletin

Volumn 47, Issue 5, 1999, Pages 621-632

  Masaguer, Christian F ^a   Casariego, Isabel ^a   Raviña, Enrique ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

5 HT(2A) affinity; Aminoalkyl 4 oxotetrahydroindole; Antipsychotic; D2 affinity

Indexed keywords

3 ETHYL 2 METHYL 6 [4 (2 METHOXYPHENYL)PIPERAZINYL]METHYL 4,5,6,7 TETRAHYDROINDOL 4 ONE; 3 ETHYL 2 METHYL 6 [4 (4 FLUOROBENZOYL)PIPERIDINYL]METHYL 4,5,6,7 TETRAHYDROINDOL 4 ONE; 3 ETHYL 2 METHYL 6 [4 (6 FLUORO 1,2 BENZISOXAZOL 3 YL)PIPERIDINYL]METHYL 4,5,6,7 TETRAHYDROINDOL 4 ONE; 3 ETHYL 2 METHYL 6 [4 [3 (4 FLUOROBENZOYL) 1 PROPYL]PIPERAZINYL]METHYL 4,5,6,7 TETRAHYDROINDOL 4 ONE; 5 AMINOETHYL 4 OXOTETRAHYDROINDOLE DERIVATIVE; 6 AMINOMETHYL 4 OXOTETRAHYDROINDOLE DERIVATIVE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BUTYROPHENONE DERIVATIVE; CINUPERONE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MOLINDONE; N (3 ETHYL 2 METHYL 4 OXO 4,5,6,7 TETRAHYDRO 5 INDOYLETHYL) 4 (4 FLUOROBENZOYL)PIPERIDINE; N [BETA (3 ETHYL 2 METHYL 4 OXO 4,5,6,7 TETRAHYDRO 5 INDOYLETHYL)] N(4) (2 METHOXYPHENYL)PIPERAZINE; N [BETA (3 ETHYL 2 METHYL 4 OXO 4,5,6,7 TETRAHYDRO 5 INDOYLETHYL)] N(4) PHENYLPIPERAZINE; N [BETA (3 ETHYL 2 METHYL 4 OXO 4,5,6,7 TETRAHYDRO 5 INDOYLETHYL)]MORPHOLINE; N [BETA (3 ETHYL 2 METHYL 4 OXO 4,5,6,7 TETRAHYDRO 5 INDOYLETHYL)]PIPERAZINE; NEUROLEPTIC AGENT; OCAPERIDONE; OLANZAPINE; PIQUINDONE; QF 0400B; QF 0402B; QF 0405B; QF 0407B; QF 0408B; QF 0409B; QF 0410B; RISPERIDONE; SEROTONIN RECEPTOR; SERTINDOLE; UNCLASSIFIED DRUG;

ARTICLE; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRAPYRAMIDAL SYMPTOM; PHYSICAL CHEMISTRY; RECEPTOR AFFINITY; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

EID: 0033032752     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.47.621     Document Type: Article

References (49)

1. Reynolds G. P., Trends Pharmacol. Sci., 13, 116-121 (1992).
2. Martin A. R., "Antipsychotic Agents," in Burger's Medicinal Chemistry, 5th ed.; ed. by Wolf M. E., Wiley-Interscience, New York, 1997, Vol. 5, p. 195.
3. a) Lednicer D., Mitscher L. A., "The Organic Chemistry of Drug Synthesis," Vol. 2, Wiley Interscience, New York, 1980, p. 4559;
4. b) Horu A. S, "Dopamine Receptors," in Comprehensive Medicinal Chemistry, Vol. 3, ed. by Hansch C., Sammes P. G., Taylor J. B., Pergamon Press, Oxford, 1990, p. 133.
5. Olson G. L., Ho-Chuen C., Morgan D. K., Blount J. F., Todaro L., Berger L., Davidson A. B., Boff E., J. Med. Chem., 24, 1026-1034 (1981).
6. Seeman P., Chou-Wong M., Tadesco J., Wong K., Nature (London), 261, 717-719 (1976).
7. Seeman P., Lee T., Science, 188, 184-189 (1975).
8. Peroutka S. J., Snyder S. H., Am. J. Psychiatry, 173, 1518-1522 (1980).
9. Sanberg P. R., Nature (London), 284, 472-473 (1980).
10. Seeman P., Bzowej N. H., Guan H. C., Bergeron C., Becker L. E., Reynols G. P., Bird E. D., Riedeger P., Jelliger K., Watanabe S., Tourtellote W. W., Synapse, 1, 399-404 (1987).
11. Nowak K., Welsch-Kunze S., Kuschinsky K., Naunyn-Schmiedeberg's Arch. Pharmacol., 337, 385-391 (1988).
12. Fitton A., Heel R. C., Drugs, 40, 722-747 (1990).
13. Schwarz J. T., Brotman A. W., Drugs, 44, 981-985 (1992).
14. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D., N. Engl. J. Med., 337, 809-815 (1997).
15. Sanders-Buch E., Mayer S. E, "Agonistas y antagonista de los receptores de 5-hidroxitriptamina," in Goodman & Gilman. Las bases farmacológicas de la terapeutica., 9th ed., Molinoff P. B., Ruddon R. W., eds., McGraw-Hill Interamericana, México, 1996, pp. 265-280.
16. Meltzer H. Y., Matsubara S., Lee J. C., J. Pharmacol. Exp. Ther., 251, 238-246 (1989).
17. Roth B. L., Meltzer H. Y., "The role of Serotonin in Schizophenia," in Psychopharmacology: The Fourth Generation of Progress, Bloom F. E., Kupfer D. J., eds., Raven Press, Ltd., New York, 1995, pp. 1215-1227.
18. Meltzer H. Y., Matsubara S., Lee J. C., Psychopharmacol. Bull., 25, 390-392 (1989).
19. Roth B. L., Tandra S., Burgess L. H., Sibley D. R., Meltzer H. Y., Psychopharmacology, 120, 365-368 (1995).
20. a) Megens A. H. P., Kennis L. E. J., "Risperidone and Related 5-HT2/D2 Antagonists: a New Type of Antipsychotic Agent," in Progress in Medicinal Chemistry, Ellis G. P., Luscombe D. K., eds., Elsevier Sci., 1996, Vol. 33, p. 186;
21. b) Beasley C. M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S., Neuropsychopharmacol., 14, 111-123 (1996);
22. c) Conley R. R., Buchanan R. W., Schizophrenia Bull., 23, 663-674 (1997).
23. Lowe III J. A., Curr. Med. Chem., 1, 50-60 (1994).
24. Gleason S. D., Shannon H. E., Psychopharmacology. Berl., 129, 79-84 (1997).
25. Sipes T. E., Geyer M. A., Brain Res., 761, 97-104 (1997).
26. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Kumagai T., Nakazato A., Nagamine M., Yamaguchi K., Tomisawa K., Brit. J. Pharmacol., 121, 515-525 (1997).
27. Green M. F., Marshall B. D., Jr., Wirshing W. C., Ames D., Marder S. R., McGurk S., Kern R. S., Mintz J., Am. J. Psychiat., 154, 799-804 (1997).
28. Martin P., Waters N., Carlsson A., Carlsson M. L., J. Neural. Transm., 104, 561-564 (1997).
29. Padich R. A., McCloskey T. C., Kehne J. H., Psychopharmacology, 124, 107-116 (1996).
30. 2A Receptor Antagonist for the Treatment of Schizophrenia," IBS's International Conference on: Serotonin receptors. Central Nervous System. Targets for New Therapeutic Agents, Philadelphia, 1996.
31. Janssen P. A. J., Niemegeers C. J. E., Awouters F., Schelekens K. H. L., Megens A. A. H. P., Meert T. F., J. Pharmacol. Exp. Ther., 244, 685-693 (1988).
32. Megens A. A. H. P., Niemegeers C. J. E., Awouters F. H. L., J. Pharmacol. Exp. Ther., 260, 160-167 (1992).
33. Hyttel J., Arnt J., Costall B., Domeney A., Dragsted N., Lembol H. L., Meier E., Naylor R. J., Nowak G., Sanchez C., Starsfeldt T., Clin. Neuropharmacol., 15 (Suppl.1 PtA), 267A-268A (1992).
34. Lieberman J. A., Hohn C. A., Mikane J., Rai K., Pisciotta A. V., Salz B. L., Howard A., J. Clin. Psychiat., 49, 271-277 (1988).
35. Cortizo L., Santana L., Ravina E., Orallo F., Fontenla J. A., Castro E., de Ceballos M., J. Med. Chem., 34, 2242-2247 (1991).
36. Fontenla J. A., Osuna J. A., Rosa E., Castro E., Loza I., G-Ferreiro T., Calleja J. M., Sanz F., Rodriguez J., Fueyo J., Raviña E., Masaguer C. F., Vidal A., de Ceballos M., J. Med. Chem., 37, 2564-2573 (1994).
37. Raviña E., Fueyo J., Masaguer C. F., Negreira J., Cid J., Loza I., Honrubia H., Tristan H., Ferreiro T. G., Fontenla J. A., Rosa E., Calleja J. M., de Ceballos M. L., Chem. Pharm. Bull., 44, 534-541 (1996).
38. Loza I., Verde I., Orallo F., Fontenla J. A., Calleja J. M., Raviña E., Cortizo L., de Ceballos M., Bioorg. Med. Chem. Lett., 1, 717-720 (1991).
39. Raviña E., Masaguer C. F., Cid J., Casariego I., Fontenla J. A., Ferreiro T. G., Cadavid I., Loza I., de Ceballos M. L., Bioorg. Med. Chem. Lett., 5, 579-584 (1995).
40. Masaguer C. F., Raviña E., Fontenla J. A., Loza I., Bioorg. Med. Chem. Lett., 7, 913-918 (1997).
41. a) Shustke G. M., Setescak L. L., Allen R. C., Davis L., Effland R. E., Ranbom K., Kitzen J. M., Wilker J. C., Novick W. J., J. Med. Chem., 25, 36-44 (1982);
42. b) Strupczewski J. T., Allen R. C., Gardner B. A., Schmid B. L., Stache U., Glamkowski E. J., Jones M. C., Ellis D. B., Huger F. P., Dunn R. W., ibid., 28, 761-769 (1985).
43. Masaguer C. F., Raviña E., Fueyo J., Heterocycles, 34, 1303-1309 (1994).
44. Remers W. A., Roth R. H., Gibs G. J., Weiss M. J., J. Org. Chem., 36, 1232-1240 (1971).
45. Yasuhara A., Sakamoto T., Tetrahedron Lett., 39, 595-596 (1998).
46. Fuji M., Muratake H., Natsume M., Chem. Pharm. Bull., 40, 2338-2343 (1992).
47. Raviña E., Negreira J., Cid J., Masaguer C. F., Rosa E., Rivas M. E., Fontenla J. A., Loza M. I., Tristán H., Cadavid M. I., Sanz F., Lozoya E., Carotti A., Carrieri A., "Conformationally Constrained Butyrophenones with Mixed Dopaminergic (D2) and Serotoninergic (5-HT2A, 5-HT2C) Affinities. Synthesis, Pharmacology, 3D-QSAR and Molecular Modelling of Aminoalkyl Benzo and Thienocycloalkanones as Putative Atypical Antipsychotics," J. Med. Chem. (in press)
48. Kuehne M. E., Lambert B. F., J. Am. Chem. Soc., 81, 4278-4287 (1959).
49. Chapmann O. L., Fitton P., J. Am. Chem. Soc., 85, 41-47 (1963).